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Abstract 
Community pharmacy practice-based research networks (CP PBRNs) are a relatively new arena for pharmacists. While some lessons 
may be gleaned from primary care PBRNs, the experiences of CP PBRNs have much to offer the profession in terms of organization 
and practice.  In 2012, we reported on our early experiences developing the Medication Safety Research Network of Indiana (Rx-
SafeNet) after establishing the Network in 2010. Over the past 3 years, our CP PBRN of approximately 180 members has managed 
further growth by revisiting policies and procedures, maintaining CP PBRN member relationships, and preparing for financial 
sustainability. We look forward to furthering our CP PBRN projects in the coming years and collaborating with other CP PBRNs to 
enhance medication safety in Indiana and beyond. 
 
 
Introduction 
Community pharmacy practice-based research networks (CP 
PBRNs) have the potential to enhance patient care, improve 
medication usage including adherence, and foster 
collaboration among pharmacists and other healthcare 
providers.1  In 2010, a CP PBRN termed the Medication Safety 
Research Network of Indiana (Rx-SafeNet)2 was launched by 
the Purdue College of Pharmacy to connect College faculty 
with practicing community pharmacists. Rx-SafeNet’s mission 
is to improve medication safety and advance community 
pharmacy practice in Indiana through the conduct and 
dissemination of collaborative, patient-centered, practice-
based research. Despite such efforts and those like it, 
development of new CP PBRNs has remained slow compared  
 
Corresponding Author: Mary Ann Kozak, DrPH 
Purdue University College of Pharmacy 
Fifth Third Bank Faculty Office Building,  
640 Eskenazi Ave., Indianapolis, IN 46202 
Email: makozak@purdue.edu 
Phone: 317-880-5411; Fax: 317-880-0568 
to development of other healthcare PBRNs.3 Current 
literature to assist aspiring PBRNs focuses on progressive 
growth and network maturation may be thought of as 
occurring in a step-wise progression of four stages of 
development: 1) conceptualization;4 2) implementation;5  3) 
growth6 and finally, 4) maturation.4   
 
Most PBRN literature has focused on conceptualization and 
implementation challenges; for example, Rx-SafeNet5 and 
Seston et al.7 previously shared early experiences about 
laying the groundwork for their CP PBRNs, drafting policies 
and procedures, and completing early projects with a small 
number of pharmacies. However, generalizability of these 
findings are limited by the projects’ small sample size and few 
participating pharmacies.6 Further findings by Schommer 
provide suggestions for stimulating inter-network growth by 
boosting participating community pharmacies and sample 
size,8 but more research is warranted to explore the 
proposed strategies. To address the paucity of literature 
regarding the challenges facing CP PBRNs during later stages 
of development, we are sharing the experience of growing 
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Rx-SafeNet with specific challenges related to managing 
growth and sustainability. In this context, growth refers to 
the addition of pharmacies and pharmacist members, 
implementation of increasingly complex projects, and the 
movement toward greater external grant funding for 
research projects. Specifically, we are sharing techniques we 
have developed and utilized to overcome several challenges 
experienced during the growth and early maturation stages, 
including: 1) Increasing membership, 2) Staffing needs, 3) 
Revisiting policies and procedures, 4) Relationship building, 5) 
Developing project ideas, and 6) Achieving maturation.  
 
Network Overview 
Rx-SafeNet was launched in 2010 by the Purdue University 
College of Pharmacy as part of a larger initiative designed to 
enhance the community pharmacist’s role in promoting 
medication safety.5,9 The Network includes independent, 
chain, and hospital/health-system outpatient community 
pharmacies across the state of Indiana and is led by a 4-
person Executive Committee comprised of a faculty member, 
fellow, and two staff members. The Network is also 
supported by a Project Review Team (PRT), comprised of 
Purdue faculty who review proposed study protocols for 
scientific quality and feasibility. Finally, Network leadership 
also includes an Advisory Board that meets quarterly and 
shares expertise from working with other PBRNs, assists with 
strategic planning, and provides guidance concerning 
Network policies.  
 
See Table 1 for a compilation of all challenges and solutions 
presented. 
 
Challenge: Increase Membership 
To increase Network membership, as described previously,5 
formal information sessions for pharmacy staff were initially 
held in the community to raise awareness and provide 
education regarding the benefits of Network membership. 
While these sessions were valuable and resulted in new 
members, we found they attracted less than 25 pharmacists 
and technicians total.  
 
Solution: To stimulate additional interest in Rx-SafeNet and 
achieve greater attendance at information sessions, we 
worked with our College’s continuing education (CE) 
department to develop a 1 hour CE credit course for 
pharmacists and pharmacy technicians. The cost of 
developing the CE included personnel time, limited marketing 
materials (e.g., post card mailers), and space rental in some 
cases. There was no cost to participants to attend the CE 
session and refreshments were served. The CE sessions 
included a history of PBRNs, their function and examples of 
successful PBRNs.   
At the end of the CE course, attendees were invited to stay 
for an information session (not part of the CE course) 
describing Rx-SafeNet. This portion of the session included 
details of how to join, benefits and expectations of 
membership, project examples, and a question and answer 
portion. Interest in CE has increased attendance at the 
information sessions, and consequently, interest in Rx-
SafeNet. By promoting the CE course through post card 
mailers and state professional associations, we have 
delivered CE to more than 50 pharmacists and pharmacy 
technicians In addition, some of our existing members have 
utilized the CE course to educate their own pharmacists and 
technicians to enhance their understanding of what it means 
to be an Rx-SafeNet member and participate in a CP PBRN. To 
date, the CE program has been offered 6 times throughout 
the state, and currently, we have plans to offer it as a face-to-
face course with concurrent webinar streaming to reach 
more pharmacists and technicians and pharmacy managers.  
 
Challenge:  Staffing Needs 
Moving from the implementation stage into the growth stage 
resulted in the addition of approximately 160 pharmacies 
over a three-year period. Today, approximately 180 
pharmacies employing collectively about 322 pharmacists are 
members of the Network. This growth required more person 
hours to maintain Network productivity as the workload 
increased and thus, to handle day-to-day operations it was 
necessary to increase from a half-time Network Coordinator 
to a full-time Network Manager. Funding for initial projects 
completed during the first 2 years came from the overarching 
Lilly Endowment, Inc. grant that funded the new College 
community initiative. These early projects provided the 
opportunity to pilot Network operations. In terms of 
budgeting, an estimated $100,000 would be needed to cover 
salary and benefits, for the approximately 2,288 person hours 
needed to maintain CP PBRN stability during the mid-growth 
stage (2,080 hours or 100% salary coverage for a Network 
Manager, and 208 hours or 10% salary coverage for a 
Network Director). This budget estimate is based on a goal of 
three small projects per year (e.g., a project involving 5-10 
pharmacies with data collection time-limited to 6 months or 
less).  
 
Solution:  A full-time Network Manager position was created 
with the responsibility to: 1) develop project protocols, 2) 
garner project support, 3) organize and manage projects, 4) 
add new Network members, and 5) secure project funding. It 
was decided that these tasks would be well served by an 
individual with previous PBRN research, but not necessarily 
pharmacy practice experience. Consequently, Rx-SafeNet 
hired a full-time Network Manager with a Doctorate in Public 
Health and previous PBRN experience. In addition, we have 
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offset staffing needs by creating opportunities for learners 
including Doctor of Pharmacy (PharmD) students and the 
College’s Community Practice Research Fellow (beginning in 
2011). Further integration of the Fellow into Network 
activities was achieved in 2013 by having the Fellow conduct 
their primary research project in collaboration with Rx-
SafeNet.  This has enhanced the Fellow’s familiarity with 
Network procedures as well as his/her relationships with our 
members. Starting in 2013, PharmD students have become 
more involved with the Network by completing a 1-month 
rotation (i.e., advanced pharmacy practice experience [APPE]) 
during their fourth year of pharmacy school under the 
mentorship of the Rx-SafeNet Director, who is a faculty 
member in the College of Pharmacy. Since then, a total of 8 
students have completed this APPE. The objectives of this 
APPE are for students to actively participate in the College’s 
community programs, including Rx-SafeNet; to gain 
experience in research; and to interact with other learners 
including the Community Practice Research Fellow. This has 
created a “win-win” situation, as the Network receives 
additional support and the learners gain important exposure 
to community pharmacy research. In terms of student 
learners, projects have been tailored that usually could be 
completed during their one-month rotation; although, 
planning is critical due to the wide variance in the workload 
of the Network in number of submitted grant applications, 
complexity of applications and manuscripts, and timing of 
student rotations.  
 
Challenge: Revisiting Policies and Procedures 
In tandem with Network growth, it became apparent that 
changes to the Network’s policies and procedures were 
required. One example of a required policy change involved 
the Project Review Team (PRT). The PRT members, faculty in 
the Department of Pharmacy Practice, felt burdened with the 
number of studies progressing through the Network during 
each successive review period. Further, they felt that 
submitted project protocols were written in a manner that 
did not provide sufficient information for review. In addition, 
we observed confusion with existing policy regarding the PRT 
members’ role and in particular, whether they needed to 
“approve” protocols or simply offer feedback. Another 
example of a required policy change involved working with 
investigator(s) that were not Rx-SafeNet members. 
Specifically, it was important to ensure appropriate 
acknowledgment was given to Rx-SafeNet for studies that 
resulted in publication. Finally, a policy that we added 
concerned pharmacy and pharmacist confidentiality with 
respect to Rx-SafeNet membership. 
 
Solution: With respect to the PRT, streamlining the workload 
by updating the policy was needed for the PRT to function 
efficiently. Thus, the PRT policy was updated to ensure that 
investigators submit a proposal in final form as well as an IRB 
application to ensure study clarity. This updated role created 
an avenue for PRT member compensation and provided 
clarity that a review, not approval, is the expectation for PRT 
members. To compensate the PRT members, we also 
developed a policy to fund attendance to one national 
conference per year for each member, dependent upon 
available funding.  
 
With respect to investigators external to Rx-SafeNet, we have 
identified a need for better education. For example, early 
study investigators unaffiliated with the Network did not 
routinely adhere to our publication policy, which stipulates 
that investigators mention Rx-SafeNet in the methods section 
as well as the secondary title of a journal article, for example, 
“Title of Study: a study of the Medication Safety Research 
Network of Indiana.” While we had drafted a guidance 
document for collaborators previously, we have been 
working to further emphasize its content.  
 
With regard to our confidentiality policy, we have found that 
some members would rather not disclose their participation 
in the Network to other members, while other members are 
very open about their participation. Thus, we have made a 
blanket policy to keep all membership confidential. As such, 
all mass communications to Rx-SafeNet members are emailed 
under blinded copy, and membership status is not disclosed 
to anyone outside of Network/College leadership without 
member permission. We are currently in the process of 
revisiting the policy to determine if another revision is 
warranted to formalize members’ ability to wave their 
confidentiality in specific circumstances, and to encourage 
dialogue among members for the purpose of identifying 
potential pitfalls upon introducing study protocols. 
 
Challenge: Relationship Building 
One of the challenges that we discovered was to find the time 
required for pharmacists to complete human subject 
protection training for studies in which a pharmacist is a co-
investigator or participating in data collection. In carrying out 
projects during the growth stage, we noted the importance of 
incentivizing members for projects requiring human subject 
protection training to ensure participation. Also, with regard 
to our Institutional Review Board (IRB), we discovered that 
this relationship was a challenge common to PBRNs that had 
to be addressed.10-15 In some cases, we received differing 
advice from the IRB when a question emerged. For example, 
in several studies, the question arose as to whether 
pharmacists and technicians were key personnel or non-key 
personnel on several particular projects. This issue was 
important because it dictated human subject protection 
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training requirements. We had received differing opinions 
from IRB representatives regarding this issue based upon the 
individual’s involvement in the study. Another challenge was 
in building relationships with other CP PBRNs in our region 
and nationally. It became apparent during the growth phase 
that the Network could substantially benefit from 
establishing relationships with other CP PBRNs. Finally, 
another challenge has been to engage the Department of 
Pharmacy Practice faculty within our College for the purpose 
of promoting introduction of Network project ideas, and to 
develop relationships with faculty at other universities for 
this purpose.   
 
Solution: To offset the burden to pharmacists and technicians 
who may be involved in projects for time spent on human 
subjects training, we implemented a process for 
compensating both pharmacist and technician time. Member 
pharmacies receive $150 for each pharmacist and $75 for 
each pharmacy technician who completes training. In 
addition, 6 CE credits are available for training completion as 
designated by the Indiana Board of Pharmacy for pharmacists 
and pharmacy technicians. To date, thirteen member 
pharmacists have completed human subject protection 
training to engage in data collection for Network projects. No 
pharmacy technicians have completed the training to 
date.With regard to the IRB, we established a positive 
relationship with the IRB Director and commonly contact her 
directly for advice. In more than one instance, it was 
necessary to discuss the situation with the IRB Director to 
reach clarity. Previously, we shared our experiences about 
working with our IRB to create non-affiliated investigator 
agreements5 and the experiences we have shared have 
solidified the need to maintain a positive working relationship 
and open communication with the IRB.  
 
In terms of engaging other CP PBRNs to promote Network 
projects, we have been successful in establishing a 
relationship with a CP PBRN in our region and were able to 
jointly participate in a project idea introduced by an outside 
organization. The project was conducted in both PBRNs and 
we plan to work on joint projects in the future. In addition, 
AHRQ offers a PBRN conference each year, also promoting 
the opportunity to meet and potentially work with other CP 
PBRNs and other PBRNs that may be interested in our work. 
As a result of attending the PBRN conference in 2014, we 
established a working relationship with a PBRN focused on 
studies to prevent drug abuse. Ultimately, our Network was 
written into their grant proposal which was funded, including 
funding for a study within our Network. In addition, an 
investigator from another College of Pharmacy expressed 
interest in utilizing Rx-SafeNet for a pilot project that was 
successful. Plans are currently underway to use the pilot 
project as preliminary work for a larger, federal application 
that will benefit the Network and the outside investigator.  
 
Challenge: Member Engagement 
As mentioned previously, project ideas are received from 
academic investigators both within and outside of the College 
of Pharmacy, and also from Network members. Ideas from 
members are communicated by Site Coordinators; they are 
the designated contact for the participating community 
pharmacy in discussions with the Network, primarily the 
Network Manager. All of the ideas offered by the different 
groups propelled us into Network growth as we found that 
we needed to increase the number of member pharmacies to 
share the activities required of an increasing number of 
projects. In addition, it is important for Site Coordinators to 
remain engaged with the Network when they are not 
involved in a specific project. 
 
Solution: To ensure that projects are of interest to Site 
Coordinators, we established a “project idea form” for 
investigators and members early in our history to assess the 
viability of the project ideas. Individual investigators or 
pharmacist members are able to propose a research idea by 
filling out a brief 1-page project idea form located on the Rx-
SafeNet website.9 Examples of projects proposed have 
related to medication disposal, medication therapy 
management, health promotion, and pharmacist-provided 
education.  
  
After a project idea form has been submitted to Rx-SafeNet 
by fax or email, Site Coordinators are polled to determine 
their interest in the project via email. These emails are ballots 
that have embedded links; the Site Coordinator can click on 
the embedded link to cast their vote on whether they are 
interested in pursuing the project. Projects are then tracked 
to inform Site Coordinators and the College of Pharmacy 
about progress on project idea generation. To date, 24 
projects have been presented to Site Coordinators since 
inception and they voted to pursue 19 (approximately a 79% 
approval rate).  Ten projects have been completed, 1 is in the 
data collection phase, and 7 have been approved for further 
development. Of the 7 approved for development, 1 proposal 
has been funded (the previously mentioned project with the 
drug abuse PBRN) and 6 proposals did not receive federal or 
foundation funding. To keep Site Coordinators engaged when 
they are not participating in specific projects, we include 
information on Network projects in our quarterly newsletter. 
These newsletters are emailed to each Site Coordinator, 
including polling results and progression of Network projects 
to completion. We also distribute a Project Summary report 
to all members upon project completion so they are aware of 
the project outcome.  
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Challenge: Achieving Maturation 
When a PBRN reaches its maturation stage, members are 
engaged, large studies are being conducted and all studies 
are fully funded. While we continue to be successful in 
introducing studies, we still face challenges moving into 
maturation, largely as a result of sustainability concerns.  
Specifically, obtaining external funding is competitive and 
ideally, every proposed study utilizing the Network should 
have extramural funding.  
 
Solution: To gain experience among our members and 
continue to full maturation, we utilized our start-up Lilly 
Endowment, Inc. funding to facilitate several smaller projects 
since 2012. These projects have been kept purposefully small, 
with few study sites (5-10 or less pharmacies) and a short 
data collection period (typically 6 months or less). This has 
provided an opportunity to test Network infrastructure 
without requiring a large budget. However, in an effort to 
maintain the Network’s financial sustainability, we must now 
decline most investigator-initiated studies that are unable to 
obtain funding. In other words, it is a priority to seek federal 
or foundation funding for all Rx-SafeNet projects. We have 
sought several strategies to acquire funding. For example, 
after competing successfully for an internal University 
equipment grant, we were able to purchase several tablets 
for use in data collection in 2014.  
 
Finally, to better understand member needs and enhance 
grant writing, we briefly surveyed Network Site Coordinators 
in 2014 regarding preferred monetary and non-monetary 
compensation for project participation. The majority of Site 
Coordinators indicated that gift cards are the preferred 
method of payment on both small and larger studies. In 
general, we compensate $50-$75/hour (typically to the 
member pharmacy) for pharmacist time spent on projects. 
However, there are some pharmacies that cannot accept 
remuneration for pharmacists’ and/or technicians’ time on 
specific projects due to their own policy which prevents this. 
In addition, hospitality in the form of staff lunches is not 
allowed per specific policies at some pharmacies. This has 
made it difficult to incentivize pharmacies for their project 
participation.  
 
Conclusion 
Clearly, issues emerge with the progression of PBRN 
development, with each step requiring reflection to promote 
ongoing success and sustainability. At the same time, 
adjustments to Network policies and procedures may be 
required.  As described, Rx-SafeNet has progressed through 
PBRN growth and is in the process of attaining early 
maturation on its way to full maturation. We have discovered 
new challenges and lessons learned. Notably, we have been 
successful in adding 162 pharmacies to the Network and thus 
are confident in our outreach strategies. As such, we continue 
to clarifying policies for collaborators as early as possible, 
anticipating this is an area for continued vigilance as the 
network grows.  
 
Promoting sustainability will require a continued focus on 
clinician involvement in research and further emphasis on the 
importance of identifying appropriate compensation for 
clinician members. This challenge has been noted by other 
PBRN researchers.16 As we continue to make strides toward 
full maturation, more complex studies and larger 
investigative teams, receiving large, federally funded studies 
will be critical.  As Green4 notes about where primary care 
PBRNs were in 2006, it appears this is where CP PBRNs are at 
the present time: “These networks are now both a place and 
a concept. As a place, they are laboratories for surveillance 
and research. As a concept, they express the still unmet need 
for practicing clinicians to accept responsibility to improve 
clinical care by understanding what is happening in their 
practices.” Full maturation is an ongoing challenge, however 
one that will certainly ensure the practice of pharmacy a 
richer experience for patients, pharmacists, and researchers. 
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Table 1. Lessons learned in the growth and early maturation stages 
 
Challenge Solution 
Increase pharmacist membership Work with Continuing Education (CE) Department to 
develop a 1-hour course with CE credit for pharmacists 
and pharmacy technicians 
Consider staffing needs as workload increases Hire full-time Network Manager; use learners (PharmD 
students) and Fellows to assist with projects 
Revisit policies and procedures: Examples include 
Project Review Team (PRT) and collaborator education 
Compensate PRT members who review proposed 
projects with conference attendance or other incentive; 
ensure that collaborators adhere to a publication policy 
Build relationships with members regarding human 
subject protection training and with the Institutional 
Review Board (IRB); build relationships with other 
faculty and PBRNs 
Incentivize pharmacists and technicians by reimbursing 
them for time spent on human subject protection 
training; attend annual PBRN conference in Bethesda 
held in June. 
Engage members in project ideas and the timeline for 
project progress 
Ensure that projects are of interest to members by 
polling them, tracking progress and keeping members 
informed  
Achieve maturation by becoming sustainable At first, conduct projects with a small number of sites; 
at the same time, establish goals for attaining 
federal/foundation projects  
 
 
